Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Nuclear Medicine and Molecular Imaging
Published in: Nuclear Medicine and Molecular Imaging 2/2019

01-04-2019 | Positron Emission Tomography | Review

Progress of Coordination and Utilization of Zirconium-89 for Positron Emission Tomography (PET) Studies

Authors: Minh Thanh La, Van Hieu Tran, Hee-Kwon Kim

Published in: Nuclear Medicine and Molecular Imaging | Issue 2/2019

Login to get access

Abstract

Radiometals have been commonly used in medical applications, and utilization of such metals continues to be an attractive research area. In particular, a variety of radiometals have been developed and implemented for molecular imaging. For such applications, 89Zr has been one of the most interesting radiometals currently used for tumor targeting. Several chemical ligands were developed as 89Zr chelators, and new coordinating methods have also been developed more recently. In addition, immuno-positron emission tomography (PET) studies using 89Zr-labeled monoclonal antibodies have been performed by several scientists. In this review, recent advances to the coordination of 89Zr and the utilization of 89Zr in PET studies are described.
Literature
1.
Kasbollah A, Eu P, Cowell S, Deb P. Review on production of 89Zr in a medical cyclotron for PET radiopharmaceuticals. J Nucl Med Technol. 2013;41:35–41.CrossRefPubMed
2.
Zweit J, Downey S, Sharma HL. Production of no-carrier-added zirconium-89 for positron emission tomography. Appl Radiat Isot. 1991;42:199–201.CrossRef
3.
Tang Y, Li S, Yang Y, Chen W, Wei H, Wang G, et al. A simple and convenient method for production of 89Zr with high purity. Appl Radiat Isot. 2016;118:326–30.CrossRefPubMed
4.
Link JM, Krohn KA, Eary JF, Kishore R, Lewellen TK, Johnson MW, et al. 89Zr for antibody labeling and positron emission tomography. J Labeled Compd Radiopharm. 1986;23:1297–8.
5.
Dejesus OT, Nickles RJ. Production and purification of 89Zr, a potential PET antibody label. Int J Rad Appl Instrum A. 1990;41:789–90.CrossRef
6.
7.
Walther M, Gebhardt P, Grosse-Gehling P, Würbach L, Irmler I, Preusche S, et al. Implementation of 89Zr production and in vivo imaging of B-cells in mice with 89Zr-labeled anti-B-cell antibodies by small animal PET/CT. Appl Radiat Isot. 2011;69:852–7.CrossRefPubMed
8.
Siikanen J, Tran TA, Olsson TG, Strand SE, Sandell A. A solid target system with remote handling of irradiated targets for PET cyclotrons. Appl Radiat Isot. 2014;94:294–301.CrossRefPubMed
9.
Meijs WE, Herscheid JDM, Haisma HJ, Wijbrandts R, van Langevelde F, Van Leuffen PJ, et al. Production of highly pure no-carrier added 89Zr for the labelling of antibodies with a positron emitter. Appl Radiat Isot. 1994;45:1143–7.CrossRef
10.
Queern SL, Aweda TA, Massicano AVF, Clanton NA, El Sayed R, Sader JA, et al. Production of Zr-89 using sputtered yttrium coin targets. Nucl Med Biol. 2017;50:11–6.CrossRefPubMed
11.
Pandey MK, Engelbrecht HP, Byrne JF, Packard AB, DeGrado TR. Production of 89Zr via the 89Y(p,n)89Zr reaction in aqueous solution: effect of solution composition on in-target chemistry. Nucl Med Biol. 2014;41:309–16.CrossRefPubMed
12.
Uddin MS, Khandaker MU, Kim KS, Lee YS, Lee MW, Kim GN. Excitation functions of the proton induced nuclear reactions on natural zirconium. Nucl Inst Meth Phys Res B. 2008;266:13–20.CrossRef
13.
Kandil SA, Spahn I, Scholten B, Saleh ZA, Saad SMM, Coenen HH, et al. Excitation functions of (α,xn) reactions on natRb and natSr from threshold up to 26MeV: possibility of production of 87Y, 88Y and 89Zr. Appl Radiat Isot. 2007;65:561–8.CrossRefPubMed
14.
Lewis VE, Zieba KJ. A transfer standard for d + t neutron fluence and energy. Nucl Inst Meth. 1980;174:141–4.CrossRef
15.
Sadeghi M, Enferadi M, Bakhtiari M. Accelerator production of the positron emitter zirconium-89. Ann Nucl Energy. 2012;41:97–103.CrossRef
16.
Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010;51:1293–300.CrossRefPubMed
17.
Meijs WE, Haisma HJ, Van Der Schors R, Wijbrandts R, Van Den Oever K, Klok RP, et al. A facile method for the labeling of proteins with zirconium isotopes. Nucl Med Biol. 1996;23:439–48.CrossRefPubMed
18.
Verel I, Visser GWM, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GAMS. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271–81.PubMed
19.
Lewis MR, Shively JE. Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions. Bioconjug Chem. 1998;9:72–86.CrossRefPubMed
20.
Perk LR, Vosjan MJWD, Visser GWM, Budde M, Jurek P, Kiefer GE, et al. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging. 2010;37:250–9.CrossRefPubMed
21.
Vosjan MJWD, Perk LR, Visser GWM, Budde M, Jurek P, Kiefer GE, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5:739.CrossRefPubMed
22.
Gao F, Ieritano C, Chen KT, Dias GM, Rousseau J, Bénard F, et al. Two bifunctional desferrioxamine chelators for bioorthogonal labeling of biovectors with zirconium-89. Org Biomol Chem. 2018;16:5102–6.CrossRefPubMed
23.
White DL, Durbin PW, Jeung N, Raymond KN. Specific sequestering agents for the actinides. 16. Synthesis and initial biological testing of polydentate oxohydroxypyridinecarboxylate ligands. J Med Chem. 1988;31:11–8.CrossRefPubMed
24.
Allott L, Da Pieve C, Meyers J, Spinks T, Ciobota DM, Kramer-Marek G, et al. Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89. Chem Commun. 2017;53:8529–32.CrossRef
25.
Patra M, Bauman A, Mari C, Fischer CA, Blacque O, Häussinger D, et al. An octadentate bifunctional chelating agent for the development of stable zirconium-89 based molecular imaging probes. Chem Commun. 2014;50:11523–5.CrossRef
26.
Vugts DJ, Klaver C, Sewing C, Poot AJ, Adamzek K, Huegli S, et al. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET. Eur J Nucl Med Mol Imaging. 2017;44:286–95.CrossRefPubMed
27.
Guérard F, Lee Y-S, Tripier R, Szajek LP, Deschamps JR, Brechbiel MW. Investigation of Zr(iv) and 89Zr(iv) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging. Chem Commun. 2013;49:1002–4.CrossRef
28.
Rousseau J, Zhang Z, Wang X, Zhang C, Lau J, Rousseau E, et al. Synthesis and evaluation of bifunctional tetrahydroxamate chelators for labeling antibodies with 89Zr for imaging with positron emission tomography. Bioorganic Med Chem Lett. 2018;28:899–905.CrossRef
29.
Zhai C, Summer D, Rangger C, Franssen GM, Laverman P, Haas H, et al. Novel bifunctional cyclic chelator for 89Zr labeling–radiolabeling and targeting properties of RGD conjugates. Mol Pharm. 2015;12:2142–50.CrossRefPubMedPubMedCentral
30.
Adams CJ, Wilson JJ, Boros E. Multifunctional desferrichrome analogues as versatile 89Zr(IV) chelators for immunoPET probe development. Mol Pharm. 2017;14:2831–42.CrossRefPubMedPubMedCentral
31.
Liu S, Edwards DS. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug Chem. 2001;12:7–34.CrossRefPubMed
32.
Seibold U, Wängler B, Wängler C. Rational design, development, and stability assessment of a macrocyclic four-hydroxamate-bearing bifunctional chelating agent for 89Zr. Chem Med Chem. 2017;12:1555–71.CrossRefPubMed
33.
Deri MA, Ponnala S, Zeglis BM, Pohl G, Dannenberg JJ, Lewis JS, et al. Alternative chelator for 89Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO). J Med Chem. 2014;57:4849–60.CrossRefPubMedPubMedCentral
34.
Bhatt NB, Pandya DN, Xu J, Tatum D, Magda D, Wadas TJ. Evaluation of macrocyclic hydroxyisophthalamide ligands as chelators for zirconium-89. PLoS One. 2017;12:e0178767–e77.CrossRefPubMedPubMedCentral
35.
Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110:2858–902.CrossRefPubMedPubMedCentral
36.
Pandya DN, Bhatt N, Yuan H, Day CS, Ehrmann BM, Wright M, et al. Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. Chem Sci. 2017;8:2309–14.CrossRefPubMed
37.
Börjesson PKE, Jauw YWS, Boellaard R, de Bree R, Comans EFI, Roos JC, et al. Performance of immuno–positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006;12:2133–40.CrossRefPubMed
38.
Rizvi SN, Visser OJ, Vosjan MJ, van Lingen A, Hoekstra OS, Zijlstra JM, et al. Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using 89Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging. 2012;39:512–20.CrossRefPubMedPubMedCentral
39.
Gaykema SBM, Brouwers AH, Lub-de Hooge MN, Pleijhuis RG, Timmer-Bosscha H, Pot L, et al. 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med. 2013;54:1014–8.CrossRefPubMed
40.
van Asselt SJ, Oosting SF, Brouwers AH, Bongaerts AHH, de Jong JR, Lub-de Hooge MN, et al. Everolimus reduces 89Zr-bevacizumab tumor uptake in patients with neuroendocrine tumors. J Nucl Med. 2014;55:1087–92.CrossRefPubMed
41.
den Hollander MW, Bensch F, Glaudemans AW, Oude Munnink TH, Enting RH, den Dunnen WF, et al. TGF-β antibody uptake in recurrent high-grade glioma imaged with 89Zr-fresolimumab PET. J Nucl Med. 2015;56:1310–4.CrossRef
42.
Lamberts LE, Menke-van der Houven van Oordt CW, ter Weele EJ, Bensch F, Smeenk MM, Voortman J, et al. ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody–drug conjugate treatment. Clin Cancer Res. 2016;22:1642–52.CrossRefPubMed
43.
van Loon J, Even AJG, Aerts HJWL, Öllers M, Hoebers F, van Elmpt W, et al. PET imaging of zirconium-89 labelled cetuximab: a phase I trial in patients with head and neck and lung cancer. Radiother Oncol. 2017;122:267–73.CrossRefPubMed
44.
Jauw YWS, Zijlstra JM, de Jong D, Vugts DJ, Zweegman S, Hoekstra OS, et al. Performance of 89Zr-labeled-rituximab-PET as an imaging biomarker to assess CD20 targeting: a pilot study in patients with relapsed/refractory diffuse large B cell lymphoma. PLoS One. 2017;12:e0169828.CrossRefPubMedPubMedCentral
45.
Bensch F, Lamberts LE, Smeenk MM, Jorritsma-Smit A, Lub-de Hooge MN, Terwisscha van Scheltinga AGT, et al. 89Zr lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment in patients with solid tumors. Clin Cancer Res. 2017;23:6128–37.CrossRefPubMedPubMedCentral
46.
van Es SC, Brouwers AH, Mahesh SVK, Leliveld-Kors AM, de Jong IJ, Lub-de Hooge MN, et al. 89Zr-bevacizumab PET: potential early read out for efficacy of everolimus in metastatic renal cell carcinoma patients. J Nucl Med. 2017;58:905–10.CrossRefPubMed
47.
Bensch F, Brouwers AH, Lub-de Hooge MN, de Jong JR, van der Vegt B, Sleijfer S, et al. 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. Eur J Nucl Med Mol Imaging. 2018;45:2300–6.CrossRefPubMedPubMedCentral
48.
Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852–8.CrossRefPubMed
49.
Ulaner GA, Hyman DM, Ross DS, Corben A, Chandarlapaty S, Goldfarb S, et al. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET/CT. J Nucl Med. 2016;57:1523–8.CrossRefPubMedPubMedCentral
50.
Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database of Syst Rev. 2012.
51.
Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, et al. Optimal regimen of trastuzumab in combination with oxaliplatin/capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. BMC Cancer. 2016;16:68.CrossRefPubMedPubMedCentral
52.
Gaykema SBM, Schröder CP, Vitfell-Rasmussen J, Chua S, Oude Munnink TH, Brouwers AH, et al. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. Clin Cancer Res. 2014;20:3945–54.CrossRefPubMed
53.
Bahce I, Huisman MC, Verwer EE, Ooijevaar R, Boutkourt F, Vugts DJ, et al. Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer. EJNMMI Res. 2014;4:35.CrossRefPubMedPubMedCentral
54.
Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, et al. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. J Nucl Med. 2015;56:63–9.CrossRefPubMed
55.
Oordt CWM-vH, Gootjes EC, Huisman MC, Vugts DJ, Roth C, Luik AM, et al. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget. 2015;6:30384–93.
56.
Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, et al. 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:2093–105.CrossRefPubMedPubMedCentral
57.
ter Weele EJ, Terwisscha van Scheltinga AGT, Kosterink JGW, Pot L, Vedelaar SR, Lamberts LE, et al. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with 89Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts. Oncotarget. 2015;6:42081–90.PubMedPubMedCentral
Metadata
Title
Progress of Coordination and Utilization of Zirconium-89 for Positron Emission Tomography (PET) Studies
Authors
Minh Thanh La
Van Hieu Tran
Hee-Kwon Kim
Publication date
01-04-2019
Publisher
Springer Berlin Heidelberg
Published in
Nuclear Medicine and Molecular Imaging / Issue 2/2019
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-019-00584-z

Other articles of this Issue 2/2019

Nuclear Medicine and Molecular Imaging 2/2019 Go to the issue

Case Report

Gallbladder Paraganglioma Associated with SDHD Mutation: a Potential Pitfall on 18F-FDOPA PET Imaging

Case Report

Tracer Accumulation in Relation to Venous Thrombus on 18F-DOPA PET/CT in a Case of Persistent Hyperinsulinemic Hypoglycemia of Infancy

Original Article

Development of Predictive Models in Patients with Epiphora Using Lacrimal Scintigraphy and Machine Learning

Perspective

Current Status and Growth of Nuclear Theranostics in Singapore

Perspective

Theranostics in Bangladesh: Current Status, Challenges, and Future Perspective

Original Article

Assessment of Left Ventricular Ejection Fraction by Thallium-201 Myocardial SPECT-CT in Patients with Angina Pectoris: Comparison with 2D Echocardiography